Active vaccine
| 32507409 2020. Assessment of risk of disease enhancement with COVID-19 vaccines. |
32105090 2020. Immune responses in COVID-19 and potential vaccines: Lessons learned from SARS and MERS epidemic
| 32377694 2020. Towards effective COVID19 vaccines: Updates, perspectives and challenges (Review) |
32183941 2020. A Sequence Homology and Bioinformatic Approach Can Predict Candidate Targets for Immune Responses to SARS-CoV-2
32298218 2020. Potential for developing a SARS-CoV receptor-binding domain (RBD) recombinant protein as a heterologous human vaccine against coronavirus infectious disease (COVID)-19
32209231 2020. Computers and viral diseases Preliminary bioinformatics studies on the design of a synthetic vaccine and a preventative peptidomimetic antagonist against the SARS-CoV-2 (2019-nCoV, COVID-19) coronavirus
32219057 ä. The SARS-CoV-2 Vaccine Pipeline: an Overview
32148172 2020. Timely development of vaccines against SARS-CoV-2
32269766 2020. In silico identification of vaccine targets for 2019-nCoV
32265848 2020. Subunit Vaccines Against Emerging Pathogenic Human Coronaviruses
32300370 2020. Can an effective SARS-CoV-2 vaccine be developed for the older population?
32259480 ä. SARS-CoV-2 Vaccines: Status Report
32291382 2020. Coronavirus Vaccines: Light at the End of the Tunnel
32352026 2020. Epitope based vaccine prediction for SARS-COV-2 by deploying immuno-informatics approach
32295479 2020. Reverse vaccinology approach to design a novel multi-epitope vaccine candidate against COVID-19: an in silico study
32372051 ä. Bioinformatic prediction of potential T cell epitopes for SARS-Cov-2
32335161 ä. In the search of potential epitopes for Wuhan seafood market pneumonia virus using high order nullomers
32232474 ä. Human Challenge Studies to Accelerate Coronavirus Vaccine Licensure
32348489 ä. COVID-19: Is Everything Appropriate to Create an Effective Vaccine?
32328406 ä. Vaccines for SARS-CoV-2: Lessons from Other Coronavirus Strains
32022276 2020. Immunoinformatics?aided identification of T cell and B cell epitopes in the surface glycoprotein of 2019?nCoV
32249203 ä. Microneedle array delivered recombinant coronavirus vaccines: Immunogenicity and rapid translational development
32353328 2020. What policy makers need to know about COVID-19 protective immunity
32171450 2020. Identification of potential cross-protective epitope between a new type of coronavirus (2019-nCoV) and severe acute respiratory syndrome virus
32265331 2020. Single-Dose, Intranasal Immunization with Recombinant Parainfluenza Virus 5 Expressing Middle East Respiratory Syndrome Coronavirus (MERS-CoV) Spike Protein Protects Mice from Fatal MERS-CoV Infection
32355330 ä. Inactivated vaccine for SARS-CoV-2
32289117 2020. Novel decoy cellular vaccine strategy utilizing transgenic antigen-expressing cells as immune presenter and adjuvant in vaccine prototype against SARS-CoV-2 virus
32346092 ä. Cancer therapy tool informs COVID-19 vaccines
32194995 2020. The outbreak of SARS-CoV-2 pneumonia calls for viral vaccines
32229574 2020. News Feature: Avoiding pitfalls in the pursuit of a COVID-19 vaccine
32347054 2020. Strategies for vaccine development of COVID-19
32304139 ä. Progress and Concept for COVID?19 Vaccine Development
32295153 2020. What Does Plant-Based Vaccine Technology Offer to the Fight against COVID-19?
32235387 2020. Progress and Prospects on Vaccine Development against SARS-CoV-2
32106567 2020. Preliminary Identification of Potential Vaccine Targets for the COVID-19 Coronavirus (SARS-CoV-2) Based on SARS-CoV Immunological Studies
32249063 ä. Neutralizing Antibodies against SARS-CoV-2 and Other Human Coronaviruses
32362491 ä. Neutralizing Antibodies against SARS-CoV-2 and Other Human Coronaviruses: (Trends in Immunology 41, 355?359; 2020)
32340998 2020. Covid-19: What do we know so far about a vaccine?
32366511 2020. Developing a vaccine for covid-19
32379348 2020. 3CL hydrolase-based multiepitope peptide vaccine against SARS-CoV-2 using immunoinformatics
32320059 2020. Potential of live pathogen vaccines for defeating the COVID-19 pandemic: history and mechanism
32285942 2020. Defining Protective Epitopes for COVID-19 Vaccination Models
32375002 ä. Deconvoluting Lipid Nanoparticle Structure for Messenger RNA Delivery
32366816 2020. An Evidence Based Perspective on mRNA-SARS-CoV-2 Vaccine Development
32376359 ä. Design of a peptide-based subunit vaccine against novel coronavirus SARS-CoV-2
32355243 2020. Scores of coronavirus vaccines are in competition - how will scientists choose the best?
32227757 2020. Developing Covid-19 Vaccines at Pandemic Speed
32234130 2020. Progress and challenge of vaccine development against 2019 novel coronavirus (2019-nCoV)
32245869 2020. Possible treatment of Covid-19 with a therapeutic vaccine
32221001 2020. Possible method for the production of a Covid-19 vaccine
32301312 2020. Vaccins anti-covid-19 : les recherches de johnson & johnson, sanofi et pasteur
32355008 2020. COVID-19 shot protects monkeys
32300225 2020. On the front lines of the coronavirus-vaccine battle
32346146 2020. The race for coronavirus vaccines: a graphical guide
32376603 ä. Development of an inactivated vaccine candidate for SARS-CoV-2
32377399 2020. COVID-19 vaccines: breaking record times to first-in-human trials
C7152890 2020. Biomimetic nanoparticles as universal influenza vaccine
| C7167691 2020. (Deutsche Szene) Schutz vor und Hilfe bei Covid19 Infektionen |
30993690 2019. Emerging viruses and current strategies for vaccine intervention
32259744 2020. DNA vaccines: prime time is now
32387642 2020. Innovations in structure-based antigen design and immune monitoring for next generation vaccines
32344202 2020. Impact of immune enhancement on Covid-19 polyclonal hyperimmune globulin therapy and vaccine development
32318055 2020. Better Epitope Discovery, Precision Immune Engineering, and Accelerated Vaccine Design Using Immunoinformatics Tools
16022774 2005. (+)SARS Vaccine Development
28861908 2017. (+)Issues in vaccinology: Present challenges and future directions
C7202844 ä. (+)Vaccine development during global epidemics: the Zika experience
| 29329956 2018. Herd immunity: hyperimmune globulins for the 21st century |
31351923 2019. (+)First clinical trial of a MERS coronavirus DNA vaccine
16697221 2006. (+)Template-based coiled-coil antigens elicit neutralizing antibodies to the SARS-coronavirus
29852530 2020. The expanding role of mass spectrometry in the field of vaccine development
32325038 ä. (+)Safety and immunogenicity of a candidate Middle East respiratory syndrome coronavirus viral-vectored vaccine: a dose-escalation, open-label, non-randomised, uncontrolled, phase 1 trial
31692019 2020. (+)Gold nanoparticle?adjuvanted S protein induces a strong antigen?specific IgG response against severe acute respiratory syndrome?related coronavirus infection, but fails to induce protective antibodies and limit eosinophilic infiltration in lungs
32377399 2020. COVID-19 vaccines: breaking record times to first-in-human trials
32376359 2020. Design of a peptide-based subunit vaccine against novel coronavirus SARS-CoV-2
32418793 2020. An effective CTL peptide vaccine for Ebola Zaire Based on Survivors? CD8+ targeting of a particular nucleocapsid protein epitope with potential implications for COVID-19 vaccine design
32381478 2020. Enabling emergency mass vaccination: Innovations in manufacturing and administration during a pandemic
32483236 2020. Two linear epitopes on the SARS-CoV-2 spike protein that elicit neutralising antibodies in COVID-19 patients.
32471334 2020. Particulate multivalent presentation of the receptor binding domain induces protective immune responses against MERS-CoV.
32437478 2020. Harnessing the natural anti-glycan immune response to limit the transmission of enveloped viruses such as SARS-CoV-2.
32463026 2020. A Novel Vaccine Employing Non-Replicating Rabies Virus Expressing Chimeric SARS-CoV-2 Spike Protein Domains: Functional Inhibition of Viral/Nicotinic Acetylcholine Receptor Complexes.
32498742 2020. SARS-CoV-2 (COVID-19) Vaccine Development and Production: An Ethical Way Forward.
32555466 2020. COVIDep: a web-based platform for real-time reporting of vaccine target recommendations for SARS-CoV-2.
32497168 2020. On setting expectations for a SARS-CoV-2 Vaccine.
32492123 2020. The Importance of Advancing SARS-CoV-2 Vaccines in Children.
32393526 2020. A strategic approach to COVID-19 vaccine R&D.
32385100 2020. Rapid COVID-19 vaccine development.
32527802 2020. The receptor binding domain of the viral spike protein is an immunodominant and highly specific target of antibodies in SARS-CoV-2 patients.
32132669 ä. Novel antibody epitopes dominate the antigenicity of spike glycoprotein in SARS-CoV-2 compared to SARS-CoV
32380868 2020. Development of SARS-CoV-2 vaccines: should we focus on mucosal immunity?
32442040 2020. SARS-CoV-2, from its current highly contagious spreading toward the global development of an effective and safe vaccine: challenges and uncertainties.
32419646 2020. Design of multi-epitope vaccine candidate against SARS-CoV-2: a in-silico study.
32437587 2020. COVID-19 vaccines: knowing the unknown.
32460358 2020. The early landscape of COVID-19 vaccine development in the UK and rest of the world.
32441894 2020. Why Challenge Trials of SARS-CoV-2 Vaccines Could Be Ethical Despite Risk of Severe Adverse Events.
32427644 2020. Severe Acute Respiratory Syndrome Coronavirus 2 Vaccines: Setting Expectations Appropriately.
32203367 2020. Coronavirus vaccines: five key questions as trials begin.
32472069 2020. Questions remain following first COVID-19 vaccine results.
32273621 2020. If a coronavirus vaccine arrives, can the world make enough?
32473352 2020. Understanding the B and T cell epitopes of spike protein of severe acute respiratory syndrome coronavirus-2: A computational way to predict the immunogens.
32485211 2020. Advances in skin science enable the development of a COVID-19 Vaccine.
32499988 2020. Protective Adaptive Immunity Against Severe Acute Respiratory Syndrome Coronaviruses 2 (SARS-CoV-2) and Implications for Vaccines.
32505245 2020. COVID-19 vaccine development pipeline gears up.
32496238 2020. COVID-19 vaccine development and the way forward.
32325036 ä. (+)Two Middle East respiratory syndrome vaccines: first step for other coronavirus vaccines?
32397182 2020. (+)Influenza Virus Like Particles (VLPs): Opportunities for H7N9 Vaccine Development.
32386655 2020. Influence of immune aging on vaccine responses
32497149 2020. In silico veritas? Potential limitations for SARS-CoV-2 vaccine development based on T-cell epitope prediction.
32517882 2020. Immunoinformatics-guided designing of epitope-based subunit vaccines against the SARS Coronavirus-2 (SARS-CoV-2).
32405164 2020. 2019-nCoV - Towards a 4th generation vaccine.
32525830 2020. A vaccine is not too far for COVID-19.
32365191 2020. Balancing Expediency and Scientific Rigor in SARS-CoV-2 Vaccine Development.
32108359 2020. Development of epitope-based peptide vaccine against novel coronavirus 2019 (SARS-COV-2): Immunoinformatics approach.
32516041 2020. The quest to find an effective vaccine for COVID-19.
32451112 2020. Race for a COVID-19 vaccine.
32404020 2020. COVID-19: The race for a vaccine.
32514102 2020. COVID-19 vaccines start moving into advanced trials.
32454128 2020. Design of a Novel Multi Epitope-Based Vaccine for Pandemic Coronavirus Disease (COVID-19) by Vaccinomics and Probable Prevention Strategy against Avenging Zoonotics.
32417398 2020. High throughput and comprehensive approach to develop multiepitope vaccine against minacious COVID-19.
32493510 2020. SARS-CoV-2 SPIKE PROTEIN: an optimal immunological target for vaccines.
32409451 2020. U.S. 'Warp Speed' vaccine effort comes out of the shadows.
32535078 2020. Vaccination strategies to combat novel corona virus SARS-CoV-2.
32450054 2020. Hydroxychloroquine prophylaxis for high-risk COVID-19 contacts in India: a prudent approach.
32473139 2020. Death threats after a trial on chloroquine for COVID-19.
32518920 2020. Caution and clarity required in the use of chloroquine for COVID-19.
32473680 2020. The starting line for COVID-19 vaccine development.
32450106 2020. Safety, tolerability, and immunogenicity of a recombinant adenovirus type-5 vectored COVID-19 vaccine: a dose-escalation, open-label, non-randomised, first-in-human trial.
32437926 2020. From SARS-CoV to SARS-CoV-2: safety and broad-spectrum are important for coronavirus vaccine development.
32533920 2020. The Improbability of the Rapid Development of a Vaccine for SARS-CoV-2.
32499636 2020. COVID-19 vaccines: neutralizing antibodies and the alum advantage.
32433465 2020. Immunogenicity of a DNA vaccine candidate for COVID-19.
}}
32528732 2020. Universal coronavirus vaccines: the time to start is now.
32509338 2020. Certainty of success: three critical parameters in coronavirus vaccine development.
32456404 2020. The vaccine journey for COVID-19: a comprehensive systematic review of current clinical trials in humans.
| 32524253 2020. mRNA Vaccines: Possible Tools to Combat SARS-CoV-2. |
32387011 2020. Tortoises, hares, and vaccines: A cautionary note for SARS-CoV-2 vaccine development.
32418794 2020. A Veterinary Vaccine Development Process Map to assist in the development of new vaccines.
32526960 2020. Immunoinformatics and Structural Analysis for Identification of Immunodominant Epitopes in SARS-CoV-2 as Potential Vaccine Targets.
32531955 2020. Prospects of Replication-Deficient Adenovirus Based Vaccine Development against SARS-CoV-2.
32513867 2020. Antibody signature induced by SARS-CoV-2 spike protein immunogens in rabbits.
32434945 2020. DNA vaccine protection against SARS-CoV-2 in rhesus macaques.
| 32585611 2020. Potential adjuvants for the development of a SARS-CoV-2 vaccine based on experimental results from similar coronaviruses. |
32548679 2020. Calling for an exponential escalation scheme in vaccine development for COVID-19.
32591957 2020. Once we have it, will we use it? A European survey on willingness to be vaccinated against COVID-19.
32543297 2020. Why do SARS-COV vaccines not exist? The pharma scientific intelligence and business model must be revisited!
32557648 2020. Vaccine development and therapeutic design for 2019-nCoV/SARS-CoV-2: Challenges and chances.
32565096 2020. Anticipating SARS-CoV-2 Vaccine Testing, Licensure, and Recommendations for Use.
32591466 2020. SARS-CoV-2 vaccines: 'Warp Speed' needs mind melds not warped minds.
32572246 2020. Preclinical data from SARS-CoV-2 mRNA vaccine.
32559452 2020. Hydroxychloroquine use in COVID-19: what is the basis for baseline tests?
32555401 2020. Optimizing safety surveillance for COVID-19 vaccines.
32592866 2020. Emerging vaccine delivery systems for COVID-19: Functionalised silica nanoparticles offer a potentially safe and effective alternative delivery system for DNA/RNA vaccines and may be useful in the hunt for a COVID-19 vaccine.
32591367 2020. Is the production of a Covid-19 vaccine using transformed Pasteurella plausible?
32461973 2020. Design of a Multiepitope-Based Peptide Vaccine against the E Protein of Human COVID-19: An Immunoinformatics Approach.
32557771 2020. How to expedite early-phase SARS-CoV-2 vaccine trials in pandemic setting-A practical perspective.
| 32606565 2020. Coronaviruses' sugar shields as vaccine candidates. |
32407708 2020. The Challenges of Vaccine Development against a New Virus during a Pandemic.
32407707 2020. Rational Vaccine Design in the Time of COVID-19.
| 32599237 2020. Designing a novel mRNA vaccine against SARS-CoV-2: An immunoinformatics approach. |
32596085 2020. Acute Respiratory Failure Secondary to COVID-19 Viral Pneumonia Managed With Hydroxychloroquine/Azithromycin Treatment.
32546606 2020. The Nucleocapsid Protein of SARS-CoV-2: a Target for Vaccine Development.
32447675 2020. "Es wird mehrere Pandemie-Impfstoffe geben" : SARS-CoV-2 / COVID-19.
32291653 2020. Vielversprechender Impfstoffkandidat gegen COVID-19 identifiziert.
32547625 2020. The journey of remdesivir: from Ebola to COVID-19.
32597077 2020. [Progress and analysis on the development of 2019-nCoV vaccine].
| 32610006 2020. Accelerating Development of SARS-CoV-2 Vaccines - The Role for Controlled Human Infection Models. |
32433634 2020. Coronavirus vaccine trials have delivered their first results - but their promise is still unclear.
32576992 2020. Latin American scientists join the coronavirus vaccine race: 'No one's coming to rescue us'.
32600777 2020. Working Hard or Hardly Working? Regulatory Bottlenecks in Developing a COVID-19 Vaccine.
32600910 2020. Logistical challenges for potential SARS-CoV-2 vaccine and a call to research institutions, developers and manufacturers.
32600909 2020. Allocation criteria for an initial shortage of a future SARS-CoV-2 vaccine and necessary measures for global immunity.
32600911 2020. Use of seasonal influenza and pneumococcal polysaccharide vaccines in older adults to reduce COVID-19 mortality.
32600908 2020. Emerging manufacturers engagements in the COVID -19 vaccine research, development and supply.
32525587 2020. Potential for elimination of SAR-CoV-2 through vaccination as inspired by elimination of multiple influenza viruses through natural pandemics or mass vaccination.
32609415 2020. SARS-CoV-2 vaccination-A plea for fast and coordinated action.
32566261 2020. Applying lessons from the Ebola vaccine experience for SARS-CoV-2 and other epidemic pathogens.
32553431 2020. Are Genetic Vaccines the Right Weapon against COVID-19?
| 32560340 2020. Vaccines against Coronaviruses: The State of the Art. |
| 32571717 2020. The Brighton Collaboration standardized template for collection of key information for benefit-risk assessment of nucleic acid (RNA and DNA) vaccines. |
| 32563608 2020. Vaccination against coronaviruses in domestic animals. |
32540271 2020. COVID-19 vaccine development: Time to consider SARS-CoV-2 challenge studies?
32595358 2020. An insight into the epitope-based peptide vaccine design strategy and studies against COVID-19.
32583729 2020. Immunoinformatics study to search epitopes of spike glycoprotein from SARS-CoV-2 as potential vaccine.
